Whether to intervene in asymptomatic patients with severe aortic stenosis and normal left ventricular ejection fraction remains controversial. The investigators therefore try to compare clinical outcomes of elective aortic valve replacement to conventional treatment and watchful waiting strategy in a prospective randomized trial.
Aortic valve replacement (AVR) therapy is obvious choice in symptomatic severe aortic stenosis (AS) patients, because it improves symptoms, LV function and survival. Therefore, the accurate diagnosis of the disease, determination of its severity and precise evaluation of patients' clinical status is essential. However, the treatment decisions and indication for AVR in asymptomatic patients with severe AS and normal left ventricular ejection fraction (LV EF) are vague and the subject of ongoing debate. The most recent European and American guidelines have class I indication for AVR in asymptomatic severe AS patients with normal LV EF only in patients already scheduled for other cardiac surgery (for example by-pass surgery). In the case of symptom positive stress test American and European guideline differs, with European guidelines having class I indication and American guidelines only IIb indication. In all those cases of asymptomatic severe AS patients with normal LV EF the level of evidence is C, in other words there are no randomized trials. The consequence is that the decisions are made individually, patient by patient, and for this reason a patient with identical echocardiographic/clinical characteristics might be operated in USA but not in Europe (or any other part in the world), and vice-versa. With the experience that has accumulated so far, there are retrospective and observational data that elective AVR might lead to favorable outcome compared to late (after symptom onset) surgery. This may especially come to attention with the understanding that annual risk of sudden cardiac death in asymptomatic severe AS patients with normal LV EF might be very similar or even a bit higher than operative mortality in experienced cardiac surgery centers. Nevertheless, the majority of cardiologist worldwide are reluctant to send their asymptomatic patient with isolated severe AS and normal LV EF to AVR, and it will probably stay like that till randomized trials give us an answer whether elective AVR is beneficial.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
157
open heart aortic valve replacement
Cardiovascular Center Aalst
Aalst, Belgium
University Clinical Center "Rebro"
Zagreb, Croatia
University Clinical Center ''Sestre milosrdnice''
Zagreb, Croatia
all cause death, Major Adverse Cardiac Event (MACE) including: ( Acute Myocardial Infarction - AMI, Stroke - CVI, unplanned hospitalization for Heart failure (HF) needing intravenous treatment
Time frame: 36 months
all cause death, Major Adverse Cardiac Event (MACE) including: ( Acute Myocardial Infarction - AMI, Stroke - CVI, unplanned hospitalization for Heart failure (HF) needing intravenous treatment
Time frame: 5 years
in-hospital and 30 days operative mortality in operated patients in both groups
Time frame: 30 days
repeat aortic valve surgery in operated patients in both groups
Time frame: 5 years
major bleeding according to consensus report from the Bleeding Academic Research Consortium
Time frame: 5 years
thromboembolic complications based on clinical symptoms, signs and imaging studies
Time frame: 5 years
repeated major adverse cardiovascular events
Time frame: 5 years
all-cause death + heart failure hospitalization
Time frame: 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University Hospital Brno
Brno, Czechia
Institute for Clinical and Experimental Medicine (IKEM)
Prague, Czechia
Hôpital Cardiologique de Haut Lévèque
Pessac, France
University Hospital Galway
Galway, Ireland
Città della Salute e della Scienza di Torino
Turin, Piedmont, Italy
Vilnius University Hospital Santariskiu klinikos
Vilnius, Lithuania
Medical University of Silesia
Katowice, Poland
...and 4 more locations